Literature DB >> 16354592

Uroplakin Ib gene transcription in urothelial tumor cells is regulated by CpG methylation.

Prue Cowled1, Irene Kanter, Lefta Leonardos, Paul Jackson.   

Abstract

Uroplakin Ib is a structural protein on the surface of urothelial cells. Levels of uroplakin Ib mRNA are dramatically reduced or absent in many transitional cell carcinomas, but the molecular mechanisms responsible remain undetermined. Previously, we showed that loss of uroplakin Ib expression correlated with CpG methylation of Sp1/NFkappaB-binding motifs within the proximal promoter. In this study, we show that reporter activity was completely blocked by the methylation of three CpG pairs in this promoter region. Gel shift analysis using purified proteins or nuclear extracts showed that Sp1 and NFkappaB bound to motifs encompassing two of the three CpG pairs. Interestingly, the methylation of these two CpG sites did not prevent the binding of proteins to the promoter in gel shift analyses. Additionally, mutation of these two CpGs did not affect reporter activity, but mutation of 6-bp fragment spanning each CpG partially inhibited reporter activity, suggesting that these sites were functional. A requirement for both Sp1 and NFkappaB in regulating reporter activity was confirmed in transfection experiments using plasmids expressing individual proteins. Our data suggest that the methylation of specific CpG sites can silence the uroplakin Ib promoter, at least in part, by blocking the binding of Sp1 and NFkappaB, although other factors may be involved.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16354592      PMCID: PMC1501173          DOI: 10.1593/neo.05364

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  27 in total

Review 1.  Tetraspanin proteins as organisers of membrane microdomains and signalling complexes.

Authors:  Mónica Yunta; Pedro A Lazo
Journal:  Cell Signal       Date:  2003-06       Impact factor: 4.315

2.  Uroplakin gene expression in normal human tissues and locally advanced bladder cancer.

Authors:  Jonathon Olsburgh; Patricia Harnden; Robert Weeks; Barbara Smith; Adrian Joyce; Geoffrey Hall; Richard Poulsom; Peter Selby; Jennifer Southgate
Journal:  J Pathol       Date:  2003-01       Impact factor: 7.996

Review 3.  Tetraspanins: molecular organisers of the leukocyte surface.

Authors:  Jacqueline M Tarrant; Lorraine Robb; Annemiek B van Spriel; Mark D Wright
Journal:  Trends Immunol       Date:  2003-11       Impact factor: 16.687

4.  Metastasis-suppressor KAI1/CD82 induces homotypic aggregation of human prostate cancer cells through Src-dependent pathway.

Authors:  Bokeun Jee; Kideok Jin; Jang-Hee Hahn; Hyung-Geun Song; Hansoo Lee
Journal:  Exp Mol Med       Date:  2003-02-28       Impact factor: 8.718

5.  Methylation of a CpG island within the uroplakin Ib promoter: a possible mechanism for loss of uroplakin Ib expression in bladder carcinoma.

Authors:  Andrea E Varga; Lefta Leonardos; Paul Jackson; Alexandra Marreiros; Prue A Cowled
Journal:  Neoplasia       Date:  2004 Mar-Apr       Impact factor: 5.715

6.  Interspecies contamination of the KM3 cell line: implications for CD63 function in melanoma metastasis.

Authors:  Gregory W Moseley; Jill Elliott; Mark D Wright; Lynda J Partridge; Peter N Monk
Journal:  Int J Cancer       Date:  2003-07-10       Impact factor: 7.396

7.  Decreased expression of KAI1 metastasis suppressor gene is a recurrence predictor in primary pTa and pT1 urothelial bladder carcinoma.

Authors:  Jing-shi Su; Kiminobu Arima; Mariko Hasegawa; Omar E Franco; Yoshiki Umeda; Makoto Yanagawa; Yoshiki Sugimura; Juichi Kawamura
Journal:  Int J Urol       Date:  2004-02       Impact factor: 3.369

8.  Uroplakin I: a 27-kD protein associated with the asymmetric unit membrane of mammalian urothelium.

Authors:  J Yu; M Manabe; X R Wu; C Xu; B Surya; T T Sun
Journal:  J Cell Biol       Date:  1990-09       Impact factor: 10.539

9.  Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA.

Authors:  S Ikeyama; M Koyama; M Yamaoko; R Sasada; M Miyake
Journal:  J Exp Med       Date:  1993-05-01       Impact factor: 14.307

10.  Uroplakins Ia and Ib, two major differentiation products of bladder epithelium, belong to a family of four transmembrane domain (4TM) proteins.

Authors:  J Yu; J H Lin; X R Wu; T T Sun
Journal:  J Cell Biol       Date:  1994-04       Impact factor: 10.539

View more
  6 in total

Review 1.  A review of the past, present, and future directions of neoplasia.

Authors:  Alnawaz Rehemtulla; Brian D Ross
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

2.  Epigenomic profiling reveals DNA-methylation changes associated with major psychosis.

Authors:  Jonathan Mill; Thomas Tang; Zachary Kaminsky; Tarang Khare; Simin Yazdanpanah; Luigi Bouchard; Peixin Jia; Abbas Assadzadeh; James Flanagan; Axel Schumacher; Sun-Chong Wang; Arturas Petronis
Journal:  Am J Hum Genet       Date:  2008-03       Impact factor: 11.025

3.  Metastatic suppressor genes inactivated by aberrant methylation in gastric cancer.

Authors:  Jian-Feng Wang; Dong-Qiu Dai
Journal:  World J Gastroenterol       Date:  2007-11-21       Impact factor: 5.742

4.  Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome.

Authors:  Hong-Ying Huang; Shahrokh F Shariat; Tung-Tien Sun; Herbert Lepor; Ellen Shapiro; Jer-Tsong Hsieh; Raheela Ashfaq; Yair Lotan; Xue-Ru Wu
Journal:  Hum Pathol       Date:  2007-08-17       Impact factor: 3.466

5.  Decreased expression of uroplakin Ia is associated with colorectal cancer progression and poor survival of patients.

Authors:  Yongzhong He; Fandong Kong; Hanpeng Du; Mingjian Wu
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

6.  Reversible and permanent effects of tobacco smoke exposure on airway epithelial gene expression.

Authors:  Jennifer Beane; Paola Sebastiani; Gang Liu; Jerome S Brody; Marc E Lenburg; Avrum Spira
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.